Loading color scheme


Cardio3 Biosciences Acquires OnCyte CAR T-Cell Portfolio from Celdara Medical

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced the acquisition of OnCyte, LLC a division of Celdara Medical, and its portfolio of immuno-oncology CAR T cell product candidates.

Read more

Virtici Launches Collaboration to Identify and Progress High Potential Preclinical Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Read more